EGFR and nasopharyngeal carcinoma: Instead, the majority of trials primarily concentrate on targeting the EGFR and the VEGF/VEGF receptor (VEGFR) pathways, as outlined in detail in “Recent clinical advancement of precision medicine in NPC” section.